Another emerging biomarker for the prediction of patient response to ICIs independent of PD-L1 expression is the tumor mutation burden (TMB), which measures the total number of somatic mutations in a tumor genome (Chan et al., 2019). The gene discussed is CD274; the disease is neoplasm.